Headquartered in the Genopole biocluster in Evry, France,
Novagali Pharma is an emerging ophthalmic pharmaceutical company specialized in ophthalmology. Its product candidate for
Vernal Keratoconjunctivitis (VKC) -
Vekacia® - has recently passed pivotal Phase III clinical trial.
Vekacia® is a topical Cyclosporine A cationic emulsion enabling an efficient and unmatched-level drug absorption in tissues of the eye leading to optimal therapeutic efficacy. This proprietary ophthalmic emulsion of Cyclosporine A will be the first therapeutic product dedicated to treatment of such a severe ocular condition.
VKC, a rare and severe form of chronic allergic conjunctivitis, is characterized by ocular discomfort, pain, itching and intense photophobia, affecting mostly children and young adults living in warm climates worldwide.
The European Medicines Agency (EMEA) has granted an orphan drug designation in May 2006 to Vekacia® for the treatment of VKC.
Clinical data recently announced by Novagali Pharma demonstrated the efficacy and tolerability of Vekacia®.
Find more details of the clinical data from the press release (a pdf file).
Comment Preview